EUVIMEDEUVIMED entdecken
Crossref

How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand‐Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic

Masanao Sasaki iD, Hiroyuki Sato, Yukari Uemura iD, Ayako Mikami iD, Nao Ichihara iD, Shigeki Fujitani iD, Masashi Kondo, Yohei Doi iD, Eriko Morino, Daisuke Tokita iD, Norio Ohmagari, Wataru Sugiura und 1 weitere

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Masanao Sasaki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan. Hauptthemen laut MEDLINE: Drug Development, Computer Simulation, COVID-19 Drug Treatment, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the coronavirus disease 2019 (COVID‐19) pandemic, there is growing interest in utilizing adaptive platform clinical trials (APTs), in which multiple drugs are compared with a single common control group, such as a placebo or standard‐of‐care group. APTs evaluate several drugs for one disease and accept additions or exclusions of drugs as the trials progress; however, little is known about the efficiency of APTs over multiple stand‐alone trials. In this study, we simulated the total development period, total sample size, and statistical operating characteristics of APTs and multiple stand‐alone trials in drug development settings for hospitalized patients with COVID‐19. Simulation studies using selected scenarios reconfirmed several findings regarding the efficiency of APTs. The APTs without staggered addition of drugs showed a shorter total development period than stand‐alone trials, but the difference rapidly diminished if patient's enrollment was accelerated during the trials owing to the spread of infection. APTs with staggered addition of drugs still have the possibility of reducing the total development period compared with multiple stand‐alone trials in some cases. Our study demonstrated that APTs could improve efficiency relative to multiple stand‐alone trials regarding the total development period and total sample size without undermining statistical validity; however, this improvement varies depending on the speed of patient enrollment, sample size, presence/absence of family‐wise error rate adjustment, allocation ratio between drug and placebo groups, and interval of staggered addition of drugs. Given the complexity of planning and implementing APT, the decision to implement APT during a pandemic must be made carefully.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentComputer SimulationCOVID-19 Drug TreatmentCOVID-19HumansSample SizePandemicsSARS-CoV-2Clinical Trials as TopicAntiviral AgentsAdaptive Clinical Trials as TopicResearch Design

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Biostatistics Section, Department of Data Science, Center of Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Center for Clinical Research, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
  • Center for Clinical Trial and Research Support, Fujita Health University School of Medicine, Aichi, Japan.

ORCID-Profile: Masanao Sasaki, Yukari Uemura, Ayako Mikami, Nao Ichihara, Shigeki Fujitani, Yohei Doi, Daisuke Tokita, Akihiro Hirakawa

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Sasaki, M., Sato, H., Uemura, Y., Mikami, A., Ichihara, N., Fujitani, S., Kondo, M., Doi, Y., Morino, E., Tokita, D., Ohmagari, N., Sugiura, W., & Hirakawa, A. (2024). How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand‐Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3224

Vancouver

Sasaki M, Sato H, Uemura Y, Mikami A, Ichihara N, Fujitani S, et al. How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand‐Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3224

BibTeX
@article{Sasaki2024,
  author = {Sasaki, Masanao and Sato, Hiroyuki and Uemura, Yukari and Mikami, Ayako and Ichihara, Nao and Fujitani, Shigeki and Kondo, Masashi and Doi, Yohei and Morino, Eriko and Tokita, Daisuke and Ohmagari, Norio and Sugiura, Wataru and Hirakawa, Akihiro},
  title = {How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand‐Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3224}
}
Kostenlos starten →